These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 29089174)
1. Clinical outcomes of elderly patients with bloodstream infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae in an Italian Internal Medicine ward. Meini S; Laureano R; Tascini C; Arena F; Fani L; Frullini A; Passaleva MT; Roberts AT; Mannini D; Sbrana F; Ripoli A; Rossolini GM Eur J Intern Med; 2018 Feb; 48():50-56. PubMed ID: 29089174 [TBL] [Abstract][Full Text] [Related]
2. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia. Tamma PD; Han JH; Rock C; Harris AD; Lautenbach E; Hsu AJ; Avdic E; Cosgrove SE; Clin Infect Dis; 2015 May; 60(9):1319-25. PubMed ID: 25586681 [TBL] [Abstract][Full Text] [Related]
3. Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis. Sfeir MM; Askin G; Christos P Int J Antimicrob Agents; 2018 Nov; 52(5):554-570. PubMed ID: 30081138 [TBL] [Abstract][Full Text] [Related]
4. Aminoglycoside versus carbapenem or piperacillin/tazobactam treatment for bloodstream infections of urinary source caused by Gram-negative ESBL-producing Enterobacteriaceae. Zohar I; Schwartz O; Yossepowitch O; David SSB; Maor Y J Antimicrob Chemother; 2020 Feb; 75(2):458-465. PubMed ID: 31691817 [TBL] [Abstract][Full Text] [Related]
5. Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamase (ESBL) or AmpC β-lactamase: A propensity score study. Meije Y; Pigrau C; Fernández-Hidalgo N; Clemente M; Ortega L; Sanz X; Loureiro-Amigo J; Sierra M; Ayestarán A; Morales-Cartagena A; Ribera A; Duarte A; Abelenda G; Rodríguez-Baño J; Martínez-Montauti J Int J Antimicrob Agents; 2019 Aug; 54(2):189-196. PubMed ID: 31075401 [TBL] [Abstract][Full Text] [Related]
6. Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae. Ofer-Friedman H; Shefler C; Sharma S; Tirosh A; Tal-Jasper R; Kandipalli D; Sharma S; Bathina P; Kaplansky T; Maskit M; Azouri T; Lazarovitch T; Zaidenstein R; Kaye KS; Marchaim D Infect Control Hosp Epidemiol; 2015 Aug; 36(8):981-5. PubMed ID: 25990361 [TBL] [Abstract][Full Text] [Related]
7. Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella. Huang SS; Lee MH; Leu HS J Microbiol Immunol Infect; 2006 Dec; 39(6):496-502. PubMed ID: 17164953 [TBL] [Abstract][Full Text] [Related]
8. Should we consider faecal colonisation with extended-spectrum β-lactamase-producing Enterobacteriaceae in empirical therapy of community-onset sepsis? Stupica D; Lusa L; Klevišar MN; Terzić S; Pirš M; Premru MM; Strle F Int J Antimicrob Agents; 2017 Oct; 50(4):564-571. PubMed ID: 28711676 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of β-Lactam/β-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia. Gudiol C; Royo-Cebrecos C; Abdala E; Akova M; Álvarez R; Maestro-de la Calle G; Cano A; Cervera C; Clemente WT; Martín-Dávila P; Freifeld A; Gómez L; Gottlieb T; Gurguí M; Herrera F; Manzur A; Maschmeyer G; Meije Y; Montejo M; Peghin M; Rodríguez-Baño J; Ruiz-Camps I; Sukiennik TC; Tebe C; Carratalà J; Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584145 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of empirical therapy with non-carbapenems for urinary tract infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Asakura T; Ikeda M; Nakamura A; Kodera S Int J Infect Dis; 2014 Dec; 29():91-5. PubMed ID: 25461239 [TBL] [Abstract][Full Text] [Related]
11. Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes. Freeman JT; McBride SJ; Nisbet MS; Gamble GD; Williamson DA; Taylor SL; Holland DJ Int J Infect Dis; 2012 May; 16(5):e371-4. PubMed ID: 22401750 [TBL] [Abstract][Full Text] [Related]
12. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters. Lee NY; Lee CC; Huang WH; Tsui KC; Hsueh PR; Ko WC Clin Infect Dis; 2013 Feb; 56(4):488-95. PubMed ID: 23090931 [TBL] [Abstract][Full Text] [Related]
13. Is It Time to Rethink the Notion of Carbapenem-Sparing Therapy Against Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bloodstream Infections? A Critical Review. Chastain DB; White BP; Cretella DA; Bland CM Ann Pharmacother; 2018 May; 52(5):484-492. PubMed ID: 29239220 [TBL] [Abstract][Full Text] [Related]
14. Does Quick Sepsis-Related Organ Failure Assessment Suggest the Use of Initial Empirical Carbapenem Therapy in Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Bacteria? :A Multicenter Case-Control Study. Mitsuboshi S; Tsuruma N; Watanabe K; Takahashi S; Nakashita M; Ito A; Kobayashi K; Tsugita M Jpn J Infect Dis; 2019 Mar; 72(2):124-126. PubMed ID: 30381688 [TBL] [Abstract][Full Text] [Related]
15. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Tumbarello M; Sanguinetti M; Montuori E; Trecarichi EM; Posteraro B; Fiori B; Citton R; D'Inzeo T; Fadda G; Cauda R; Spanu T Antimicrob Agents Chemother; 2007 Jun; 51(6):1987-94. PubMed ID: 17387156 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of a risk-guided strategy for empirical carbapenem use in febrile neutropenia. Khoo AL; Zhao YJ; Teng M; Ying D; Jin J; Chee YL; Poon LM; Lim SE; Koh LP; Chng WJ; Lim BP; Hsu LY; Chai LYA Int J Antimicrob Agents; 2018 Sep; 52(3):350-357. PubMed ID: 29751120 [TBL] [Abstract][Full Text] [Related]
17. Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems. Fukuchi T; Iwata K; Kobayashi S; Nakamura T; Ohji G BMC Infect Dis; 2016 Aug; 16(1):427. PubMed ID: 27538488 [TBL] [Abstract][Full Text] [Related]
18. Comparison of empirical therapy with cefoperazone/sulbactam or a carbapenem for bloodstream infections due to ESBL-producing Enterobacteriaceae. Su J; Guo Q; Li Y; Wu S; Hu F; Xu S; Wang M J Antimicrob Chemother; 2018 Nov; 73(11):3176-3180. PubMed ID: 30099554 [TBL] [Abstract][Full Text] [Related]
19. A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae. Gutiérrez-Gutiérrez B; Pérez-Galera S; Salamanca E; de Cueto M; Calbo E; Almirante B; Viale P; Oliver A; Pintado V; Gasch O; Martínez-Martínez L; Pitout J; Akova M; Peña C; Molina J; Hernández A; Venditti M; Prim N; Origüen J; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Giamarellou H; Almela M; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Mora-Rillo M; Natera C; Souli M; Bonomo RA; Carmeli Y; Paterson DL; Pascual A; Rodríguez-Baño J Antimicrob Agents Chemother; 2016 Jul; 60(7):4159-69. PubMed ID: 27139473 [TBL] [Abstract][Full Text] [Related]
20. Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae. Ng TM; Khong WX; Harris PN; De PP; Chow A; Tambyah PA; Lye DC PLoS One; 2016; 11(4):e0153696. PubMed ID: 27104951 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]